Why is Foundayo not covered by insurance? Foundayo may not be covered because it's excluded from your plan's formulary (approved drug list). This doesn't mean you can't get coverage—you can request a formulary exception with documentation showing why you specifically need Foundayo.
What to do if Foundayo is not covered by your insurance:
- 1. Confirm WHY it's not covered (formulary exclusion vs. plan exclusion vs. PA denial)
- 2. Request a formulary exception with a Letter of Medical Necessity
- 3. Document why alternatives (like Wegovy) don't work for you
- 4. If denied, appeal—many patients succeed with proper documentation
WHO THIS GUIDE IS FOR: Patients who found out Foundayo is not covered by their insurance, received a "not on formulary" denial, or want to understand their coverage options.
UNDERSTANDING YOUR DENIAL
What Does 'Foundayo Not Covered' Mean?
When your insurance says Foundayo is not covered, it typically means one of three things:
| Type of "Not Covered" | What It Means | Can You Get Coverage? |
|---|---|---|
| Formulary Exclusion | Foundayo isn't on your plan's approved drug list | Yes—request a formulary exception |
| Plan Exclusion | Your plan excludes ALL weight loss medications | Harder, but possible via comorbidity pathway or employer advocacy |
| Prior Authorization Denied | Drug IS on formulary but you didn't meet criteria | Yes—appeal the denial |
Check Your Denial Letter
Your denial letter will specify WHY Foundayo is not covered. Look for phrases like "not on formulary," "excluded benefit," or "does not meet medical necessity." This determines your next steps.
The good news: Even when Foundayo is not covered initially, many patients successfully get coverage through exception requests and appeals. A formulary exclusion is generally easier to fight than a plan-wide weight loss drug exclusion.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
UNDERSTANDING FORMULARY DECISIONS
Why Foundayo May Not Be on Your Formulary
Foundayo Is a New Drug
Foundayo (orforglipron) was FDA approved on April 1, 2026. As a newly launched medication, many insurers haven't yet finalized their formulary decisions. Coverage policies are still forming—check back with your plan periodically.
A formulary exclusion means Foundayo isn't on your insurance plan's approved drug list. Your plan's formulary is simply the list of medications it will pay for. When a drug is excluded, your insurer won't cover it—even with approval—unless you request an exception.
Here's why Foundayo may not be on your plan:
Your plan excludes weight loss medications entirely
Many employers and insurance plans have a blanket exclusion for all weight loss drugs. This is a common reason for GLP-1 denials—the plan simply doesn't cover any medications prescribed for weight management, regardless of medical necessity or FDA approval.
Your PBM hasn't added Foundayo yet
A PBM (Pharmacy Benefit Manager) manages your drug coverage. Since Foundayo just launched in April 2026, many PBMs haven't yet decided whether to include it on their formularies. They may be waiting to negotiate pricing with Eli Lilly or to see real-world outcomes before adding it.
Your PBM prefers a competitor
PBMs negotiate prices with drug manufacturers. Your PBM may have gotten a better deal on Wegovy (semaglutide) than on Foundayo (orforglipron). That makes Wegovy "preferred" and potentially excludes Foundayo. However, you can still request an exception if Wegovy doesn't work for you.
Medicare Part D restrictions
Medicare and weight-loss GLP-1s: the Medicare GLP-1 Bridge
Through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS demonstration that runs outside the Part D benefit, people with eligible Part D coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for $50 a month, if they meet CMS’s eligibility criteria and their prescriber gets prior authorization.
Source: CMS, Medicare GLP-1 Bridge · Facts in this box verified October 5, 2026
Can You Still Get Foundayo Covered?
Yes. A formulary exclusion doesn't mean you can't get Foundayo covered. You can request a formulary exception—and if you have documentation showing why formulary alternatives don't work for you, you may succeed. The key is demonstrating medical necessity for Foundayo specifically.
YOUR NEXT STEPS
How to Request a Formulary Exception
You can request a formulary exception by having your doctor submit a Letter of Medical Necessity explaining why Foundayo is required. Here's the process:
Confirm the denial reason
Review your denial letter to confirm it's a formulary exclusion (not a different denial type).
Gather documentation
Collect records of prior treatments, side effects from alternatives, BMI history, and comorbidities.
Have your provider submit the request
Your doctor submits the Letter of Medical Necessity and supporting documentation to your insurer.
Wait for the decision
Individual and small-group ACA plans must decide within 72 hours (24 hours if urgent); employer plans follow their own exception process, within 15 days under federal claims rules (72 hours if urgent).
Filing Deadline
You have 180 days from your denial date to file an exception request. Don't wait—the sooner you start, the sooner you may get coverage.
For the complete step-by-step appeal process, see our Foundayo Appeals Guide.
KEY DOCUMENTATION
What to Include in Your Exception Request
The Most Important Factor
The #1 reason exception requests succeed is documented failure or intolerance of formulary alternatives. If you've tried Wegovy and it didn't work or caused side effects, that's your strongest argument for Foundayo coverage.
Your exception request should include:
Basic Information
- Your information: Full name, date of birth, insurance ID, denial reference number
- Your diagnosis: Obesity (BMI 30+) or overweight (BMI 27+) with comorbidity
- Weight history: Current BMI and how it's changed over time
- What you've tried: Past diets, exercise programs, and medications
Why Formulary Alternatives Don't Work for You
This is the key section. You need to show why drugs your plan does cover won't work for your situation:
| Reason | Documentation Needed |
|---|---|
| Alternative didn't work | Records showing you tried Wegovy or other GLP-1 but didn't achieve adequate weight loss |
| Severe side effects | Doctor's notes documenting nausea, vomiting, or other intolerable reactions |
| Medical contraindication | A health condition that means you shouldn't take the formulary alternative |
| Dosing incompatibility | If oral Wegovy's 30-minute fasting requirement conflicts with other medications or medical routines (supporting argument—document alongside clinical reasons) |
Why Foundayo Specifically
Your doctor can cite these Foundayo advantages:
- Oral pill format: Daily tablet—no injections needed
- No food restrictions: Take any time of day with or without food (unlike oral Wegovy's 30-minute fasting requirement)
- Clinical efficacy: In the ATTAIN-1 trial, patients achieved 12.4% weight loss at 72 weeks[2]
- Different mechanism: GLP-1 receptor agonist—an alternative if semaglutide-based medications haven't worked
TEMPLATE FOR YOUR DOCTOR
Sample Formulary Exception Letter
Use this structure for your formulary exception request. Your provider should customize it with your specific medical details:
View Formulary Exception Letter Template
HEADER:
[Date]
[Insurance Company/PBM Medical Director]
[Address]
Re: Formulary Exception Request for [Patient Name]
Member ID: [Number]
DOB: [Date]
Requested Medication: Foundayo (orforglipron)
OPENING:
"Dear Medical Director,
I am writing to request a formulary exception for Foundayo (orforglipron) for my patient, [Patient Name], who has been diagnosed with [obesity/overweight with comorbidities].
I understand that Foundayo is not currently on [Insurance Plan]'s formulary. However, I believe Foundayo is medically necessary for this patient because formulary alternatives are inappropriate for the following reasons."
PATIENT HISTORY:
- Current BMI: [X] kg/m2 (weight: [X] kg, height: [X] cm)
- Weight history: [describe progression over past 1-2 years]
- Comorbid conditions: [list with ICD-10 codes]
- Prior treatment attempts: [list all diets, programs, medications with dates and outcomes]
WHY FORMULARY ALTERNATIVES ARE INAPPROPRIATE:
"[Patient] previously tried [Wegovy/other formulary drug] from [dates]. The patient experienced [inadequate weight loss of only X% / severe side effects including... / was contraindicated due to...]. Documentation attached.
Given this treatment history, continuation with formulary alternatives is not clinically appropriate."
CLINICAL RATIONALE FOR FOUNDAYO:
"Foundayo (orforglipron) is FDA-approved (April 1, 2026) for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbid condition. In the ATTAIN-1 trial, patients achieved 12.4% weight loss at 72 weeks.
Foundayo offers specific advantages for this patient:
- Oral tablet with no food restrictions (improves adherence compared to oral Wegovy's fasting requirement)
- Take any time of day (accommodates patient's schedule)
- Non-peptide GLP-1 agonist (alternative pathway if semaglutide was ineffective)"
CLOSING:
"Based on the clinical evidence and this patient's treatment history, I respectfully request that [Insurance Plan] approve a formulary exception for Foundayo. Without effective pharmacotherapy, [Patient] faces ongoing health risks including [list specific risks].
Please contact me at [phone] with any questions or to schedule a peer-to-peer discussion.
Sincerely,
[Provider Name, Credentials]
[NPI Number]"
Note: Your provider may have their own template or your insurer may have a required form. Check with your plan for specific submission requirements.
CURRENT STATUS
Foundayo Coverage by Insurer (April 2026)
Coverage Policies Are Forming
Foundayo was FDA approved on April 1, 2026. Most insurers and PBMs haven't yet announced formal coverage decisions. The information below will be updated as policies are published.
| Insurer/PBM | Status | Notes |
|---|---|---|
| CVS Caremark | Varies by plan | CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026; check your specific plan |
| Express Scripts | Not verified; check your plan’s formulary | Coverage depends on specific employer plan |
| UnitedHealthcare/OptumRx | Depends on your employer’s plan | Where covered, prior authorization is required (UHC policy 2026 P 1114-23; initial approval 6 months) |
| Aetna | Varies by plan | Aetna’s PBM is CVS Caremark, which ended its new-drug block on Foundayo on June 1, 2026; prior authorization expected when covered |
| Blue Cross Blue Shield | Varies by state/plan | Check your specific BCBS plan |
| Cigna | Not verified; check your plan’s formulary | Check your specific plan |
| Medicare Part D | Bridge: $50 per monthly fill (with conditions) | Basic Part D coverage excludes weight-loss drugs by law; Foundayo is covered through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) if you meet CMS’s criteria[3] |
How to check your coverage:
- Log into your insurance portal and search the formulary/drug list for "Foundayo" or "orforglipron"
- Call the member services number on your insurance card
- Ask your pharmacy to run a test claim
For comprehensive coverage information, see our Foundayo insurance coverage guide.
ALTERNATIVE PATHWAYS
What If Your Exception Is Denied?
Many Appeals Succeed
Many prior authorization appeals succeed when patients appeal with proper documentation—yet most patients never file an appeal. Insurance companies often rely on patients giving up. Don't be one of them.
Option 1: Appeal the Denial
If your formulary exception is denied, you have the right to appeal:
- Internal appeal: Request reconsideration with additional documentation
- Peer-to-peer review: Your doctor speaks directly with the insurance medical director
- External review: An independent reviewer evaluates your case (decision is binding on the insurer)
See our full Foundayo appeals guide for step-by-step instructions.
Option 2: Try the Formulary Alternative First
If you haven't tried Wegovy or another GLP-1 on your formulary, your insurer may require you to try it before approving Foundayo. While this is frustrating, documented failure on Wegovy becomes strong evidence for your exception request. Compare Foundayo vs. Wegovy and other GLP-1 alternatives
Option 3: Coverage for Comorbidity
Your plan may exclude weight loss medications but cover the same drug for patients with specific comorbidities. If you have:
- Sleep apnea with BMI 27+ — You may qualify under the comorbidity pathway
- Prediabetes or cardiovascular risk — Some plans cover GLP-1s for these conditions
Note: Foundayo is FDA-approved for weight management in patients with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities. It is NOT currently FDA-approved for OSA specifically.
Option 4: Talk to Your Employer
If you have employer-sponsored insurance, contact your HR department. Some employers can advocate for coverage exceptions or add GLP-1 medications to the plan at the next renewal cycle.
Option 5: Self-Pay via LillyDirect
If insurance won't cover Foundayo, you can bypass insurance entirely through LillyDirect:
- Foundayo Savings Card: With commercial insurance coverage: as low as $25/month. Without coverage: $149–$299/month (terms valid through 12/31/2026)[4]
- LillyDirect: Self-pay pricing: $149–$299/month depending on dose
- Patient assistance: Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list, so Lilly Cares is not a route to free Foundayo
For detailed cost options, see our Foundayo cost guide.
BYPASSING INSURANCE
Self-Pay Options When Insurance Won't Cover
If your formulary exception is denied and appeals aren't successful, you can still access Foundayo by paying out of pocket:
LillyDirect Pricing (April 2026)
| Dose | Monthly Price |
|---|---|
| 0.8 mg (starting) | $149/month |
| 2.5 mg (temporary price through December 31, 2026) | $149/month |
| 5.5 mg (temporary price through December 31, 2026) | $199/month |
| 9 mg - 17.2 mg | $299/month |
| 14.5 mg / 17.2 mg (lapsed 45+ days) | $349/month |
45-Day Refill Rule
For 14.5 mg and 17.2 mg doses: If you don't refill within 45 days of your last order, the price increases from $299 to $349. Set a reminder to refill on time.
Savings Card Without Insurance Coverage
If you have commercial insurance but Foundayo is NOT covered, the savings card can still help:
- Brings your cost to $149–$299/month (depending on dose)
- Maximum 10 fills per calendar year
- Valid through 12/31/2026
Note: The savings card does NOT work for Medicare, Medicaid, or other government insurance.
For complete cost details, see our Foundayo cost guide.
COMMON QUESTIONS ABOUT FORMULARY EXCLUSIONS
Frequently Asked Questions
Foundayo may not be covered for several reasons: (1) Your plan may exclude all weight loss medications, (2) Your PBM hasn't added the newly launched drug to their formulary yet, (3) Your employer chose not to include GLP-1 coverage, or (4) You have Medicare Part D: Basic Part D coverage excludes weight-loss drugs by law, but Foundayo is covered through the separate Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you meet CMS’s eligibility criteria. The good news: you can often still get coverage through a formulary exception or appeal.
A formulary exclusion means Foundayo is not on your plan's list of covered medications. Your insurance won't pay for it unless you request a formulary exception and get approved. This is different from a prior authorization denial, where the drug IS covered but you didn't meet the criteria.
Prior authorization: The drug IS on your plan's formulary, but you need approval before coverage kicks in.
Formulary exception: The drug is NOT on the formulary. You're asking your plan to make an exception and cover it anyway. This typically requires stronger documentation showing why formulary alternatives don't work for you.
It depends on your plan type. Individual and small-group ACA plans must decide within 72 hours (24 hours if urgent), and Medicare Part D plans must decide exception requests within 72 hours (24 hours if expedited). Large-group and self-funded employer plans follow their own exception process; federal claims rules allow up to 15 days (72 hours if urgent). Your doctor can request urgent review.
If your plan has a blanket exclusion for weight loss medications (not just Foundayo), getting coverage is harder. However, you may qualify through a comorbidity pathway if you have conditions like sleep apnea, prediabetes, or cardiovascular risk factors. You can also talk to your HR department about advocating for GLP-1 coverage at the next plan renewal, or consider self-pay via LillyDirect ($149–$299/month).
Yes! You have the right to appeal. Options include: (1) Internal appeal with additional documentation, (2) Peer-to-peer review where your doctor speaks directly with the insurance medical director, (3) External review by an independent third party—this decision is binding on the insurer.
YOUR PATH FORWARD
What's Next
Need Help With Your Appeal?
Many appeals succeed with proper documentation. Our complete Foundayo appeals guide walks you through the entire process—from writing your appeal letter to requesting external review.
Other Common Denial Reasons
Denied for a different reason? See our guides for other denial types:
- Medical Necessity Not Met — Insurer says treatment isn't needed
- Step Therapy Required — Must try other medications first
- BMI Criteria Not Met — Weight thresholds not satisfied
- Missing Lifestyle Documentation — Diet/exercise records needed
Not sure why you were denied? View all Foundayo denial types
Formulary Exclusion Denials for Other GLP-1s
Similar formulary denial? The appeal strategies are comparable across medications:
References
- Centers for Medicare & Medicaid Services. (2025). "CMS-0057-F: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Prior Authorization Requirements." cms.gov
- Wharton S, et al. (2025). "Orforglipron for the Treatment of Obesity." N Engl J Med. ATTAIN-1 trial results. PubMed
- Centers for Medicare & Medicaid Services. (2026). "Medicare GLP-1 Bridge Model." cms.gov; Eli Lilly and Company. (2026). "Lilly and U.S. government agree to expand access to obesity medicines." investor.lilly.com
- Eli Lilly and Company. (2026). "Foundayo Savings Card Terms and Conditions." lilly.com
Reviewed by Honest Care GLP-1 SpecialistsLast updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.